2022
DOI: 10.1038/s41591-022-02084-8
|View full text |Cite
|
Sign up to set email alerts
|

Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Abstract: Immune checkpoint inhibitors (ICIs), by reinvigorating CD8+ T cell mediated immunity, have revolutionized cancer therapy. Yet, the systemic CD8+ T cell distribution, a potential biomarker of ICI response, remains poorly characterized. We assessed safety, imaging dose and timing, pharmacokinetics and immunogenicity of zirconium-89-labeled, CD8-specific, one-armed antibody positron emission tomography tracer 89ZED88082A in patients with solid tumors before and ~30 days after starting ICI therapy (NCT04029181). N… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
44
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
2
1
1

Relationship

3
7

Authors

Journals

citations
Cited by 63 publications
(44 citation statements)
references
References 52 publications
0
44
0
Order By: Relevance
“…However, we are also keenly aware of the inherent caveat of the approach of interrogating an environment of high plasticity such as the TME in archival tissues to predict therapy outcome. There is ample clinical and experimental evidence that tumor IP can change during immunotherapy [47] [48] [49] [50]; in vivo imaging approaches could circumvent the need for on-treatment biopsies for immune profiling [51].…”
Section: Discussionmentioning
confidence: 99%
“…However, we are also keenly aware of the inherent caveat of the approach of interrogating an environment of high plasticity such as the TME in archival tissues to predict therapy outcome. There is ample clinical and experimental evidence that tumor IP can change during immunotherapy [47] [48] [49] [50]; in vivo imaging approaches could circumvent the need for on-treatment biopsies for immune profiling [51].…”
Section: Discussionmentioning
confidence: 99%
“…Patients (n = 15 (5 men, 10 women; age 33-79, mean ± SD 58 ± 13 years; weight 52-109, mean ± SD 73 ± 15 kg) with cancer with visible [ 89 Zr]mAb PET tracer uptake at day 4 p.i. in at least one tumour lesion were enrolled in this prospective study between June 2018 and February 2020 in case of a referral for an 89 Zr immunoPET acquisition to solve a clinical dilemma [14,15] or for research purposes (ClinicalTrials.gov identifiers NCT02453984 [16] and NCT04029181 [17]). All patients were scanned on the Vision PET/CT system.…”
Section: Patient Populationmentioning
confidence: 99%
“…The positive predictive value of CD8+ cytotoxic T cells was found across 17 solid cancer types, including colorectal, breast, melanoma, lung, head and neck and others ( 12 ). Because of the vital role that the CD8+ T cells play in therapy response and clinical outcome, imaging agents that are being developed for non-invasive immunomonitoring aim to characterize different aspects of the CD8+ subset – their abundance ( 13 , 14 ), activation ( 15 , 16 ) or effector function ( 17 ). The degree of specificity for CD8+ T cells among the metabolic tracers that are the focus of this mini review, varies depending on what metabolic pathway they target ( 18 ).…”
Section: Imaging Targetsmentioning
confidence: 99%